Effect of N-acetylcystein in Myocardial Infarction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01741207|
Recruitment Status : Unknown
Verified November 2012 by Tehran University of Medical Sciences.
Recruitment status was: Recruiting
First Posted : December 4, 2012
Last Update Posted : December 4, 2012
|Condition or disease||Intervention/treatment||Phase|
|Acute Myocardial Infarction||Drug: N-acetylcystein||Phase 3|
Percutaneous coronary intervention(PCI) is one of the standard therapies for acute coronary syndrome. Despite major advances in PCI procedure, impaired myocardial perfusion frequently occurred after primary PCI and resulted in a larger infarct size and increased morbidity and mortality.Reperfusion injury process can be resulted in additional death of cardiomyocytes and it is suggested that oxidative stress is a contributing factor to induce reperfusion injury.During PCI,trauma occurs to the arterial endothelium, causes the activation and aggregation of platelets.
It is estimated that approximately 25% of patients undergoing PCI have significant postprocedural creatinine kinase (CK)/creatinine kinase myocardial band (CK-MB) elevations and approximately 50% of patients have significant post-procedural troponin elevations. The most common complication of PCI is a cell damage to cardiomyocyte that can be diagnosed by postprocedure elevation of cardiac markers. N-acetylcystein have several positive effect on platelet and vascular function and infarct size.
This study is a randomized clinical trial (RCT) evaluating the effect of N-acetylcystein on biomarkers of platelet activation and coronary reperfusion in patients undergoing percutaneous coronary intervention. Double blind randomized clinical trial on 100 patients in 2 groups (intervention & control) is conducted. Patients with confirmed ST-elevation myocardial infarction included in this study. Patients were excluded if they had: emergency for cardiac bypass; cardiogenic shock and rescue percutaneous coronary intervention. Patients in Intervention group were administered 100 mg/kg Iv bolus N-acetylcystein and then 480mg intracoronary and 10mg/kg/h over 12 hours after percutaneous coronary intervention and patients in control group received standard regimens. Primary outcome was platelet activation biomarkers assessment before and 24 hours after percutaneous coronary intervention and secondary outcome was effect of N-acetylcystein on CK-MB and high sensitive Troponin T, 6 and 12 hours after percutaneous coronary intervention.Patients were assessed for coronary blood flow after percutaneous coronary intervention with the use of TIMI flow and myocardial blush grade.
Major adverse cardiac events (MACE) will be evaluated as a secondary endpoint after 30 days.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Outcomes Assessor)|
|Official Title:||Evaluation of N-acetylcystein on Biomarkers of Platelet Activation , Cardiac Necrosis and Coronary Reperfusion in Patients Undergoing Percutaneous Coronary Intervention|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||December 2012|
|Estimated Study Completion Date :||December 2012|
No Intervention: control
control This group is without N-acetylcystein : just receives standard treatment
Active Comparator: N-acetylcystein
receive N-acetylcystein in addition to standard treatment Ampoule 200 mg/ml
Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
Other Name: EXI-NACE,NAC
- Biomarkers of platelet activation (P selectin- CD40L-IL[Interleukin] 10- TGF[Transforming Growth Factor]-beta) [ Time Frame: Change from the baseline after 24 hours ]
- Cardiac Necrosis Biomarkers (CKMB, Troponin T) [ Time Frame: Change from the baseline after 12 hours ]difference between study and control group in 6 and 12 hrs after percutaneous coronary intervention
- score of coronary blood flow(TIMI flow and MBG) [ Time Frame: Change from the baseline after percutaneous coronary intervention ]
- MACE (Major Adverse Cardiac Effect) [ Time Frame: 30 days ]Defined as Need for Target Revascularization, Myocardial Infarction and Death
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01741207
|Iran, Islamic Republic of|
|Teran Heart Center||Recruiting|
|Tehran, Iran, Islamic Republic of, 1711713138|
|Contact: Azita Hajhossein Talasaz 00989123779707 email@example.com|
|Principal Investigator: Azita Hajhossein Talasaz, PharmD,BCPS|
|Sub-Investigator: Yaser Jenab, MD|
|Sub-Investigator: Mossafa Bahremand, MD|
|Sub-Investigator: Azadeh Eshraghi, Pharm D|
|Principal Investigator: Jamshid Salamzadeh, PhD|
|Sub-Investigator: Mojtaba Salarifard, MD|
|Principal Investigator:||Azita Hajhossein Talasaz, PharmD,BCPS||Tehran University of Medical Sciences|